Wave Life Sciences (NASDAQ:WVE) Shares Up 0.9%

Wave Life Sciences Ltd (NASDAQ:WVE) shares shot up 0.9% on Tuesday . The company traded as high as $21.68 and last traded at $21.80, 6,135 shares were traded during mid-day trading. A decline of 97% from the average session volume of 199,783 shares. The stock had previously closed at $21.61.

Several research firms have issued reports on WVE. ValuEngine raised Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Cowen reaffirmed a “hold” rating on shares of Wave Life Sciences in a report on Tuesday, July 30th. Mizuho reaffirmed a “buy” rating on shares of Wave Life Sciences in a report on Wednesday, September 25th. HC Wainwright set a $33.00 price target on Wave Life Sciences and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, Zacks Investment Research cut Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Wave Life Sciences presently has an average rating of “Hold” and an average target price of $49.50.

The company has a market cap of $705.15 million, a P/E ratio of -4.29 and a beta of 0.75. The company has a fifty day simple moving average of $21.51 and a 200-day simple moving average of $24.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.33 and a quick ratio of 2.33.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Monday, July 29th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.11) by ($0.11). The company had revenue of $7.63 million during the quarter, compared to the consensus estimate of $15.76 million. Wave Life Sciences had a negative net margin of 861.41% and a negative return on equity of 120.41%. On average, analysts anticipate that Wave Life Sciences Ltd will post -5.41 EPS for the current year.

Large investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in Wave Life Sciences during the 1st quarter worth about $2,317,000. Clear Street Markets LLC purchased a new stake in Wave Life Sciences during the 2nd quarter worth about $575,000. Bailard Inc. increased its holdings in Wave Life Sciences by 97.6% during the 2nd quarter. Bailard Inc. now owns 83,000 shares of the company’s stock worth $2,165,000 after purchasing an additional 41,000 shares during the period. Aperio Group LLC purchased a new stake in Wave Life Sciences during the 2nd quarter worth about $51,000. Finally, Janus Henderson Group PLC increased its holdings in Wave Life Sciences by 16.1% during the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock worth $88,505,000 after purchasing an additional 470,402 shares during the period. 88.84% of the stock is currently owned by institutional investors.

Wave Life Sciences Company Profile (NASDAQ:WVE)

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Recommended Story: How a Strangle Strategy is different from a Straddle Strategy

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit